COMMUNIQUÉS West-GlobeNewswire
-
Arbutus Announces Decision to Discontinue Development of AB-506, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B
03/10/2019 - 22:05 -
WW Announces Prepayment of Portion of Term Loan Facility
03/10/2019 - 22:20 -
Novelion Therapeutics Announces Filing of Definitive Proxy Statement in Connection with Proposed Liquidation and Other Matters
04/10/2019 - 00:21 -
Noushin Khoiny
04/10/2019 - 02:00 -
Parexel and HealthVerity Announce Strategic Partnership to Address Complex Clinical Research Questions with Customized Real-World Data Solutions
03/10/2019 - 18:00 -
Molecular You Introduces New Precision Fitness Playbook: myFitnessFx™
03/10/2019 - 20:14 -
ADMA Biologics Announces Poster Presentation at IDWeek 2019
03/10/2019 - 13:08 -
SIGA Completes Clinical Studies for IV Formulation of TPOXX®, NDA to be Submitted in 2020
03/10/2019 - 13:30 -
vTv to Host Key Opinion Leader Event to Discuss the Type 1 Diabetes Treatment Landscape and Emerging Therapies as Adjuncts to Insulin
03/10/2019 - 13:30 -
VIVUS Initiates Pay Down of Secured Debt and Announces Management Changes
03/10/2019 - 13:30 -
Exactus, Inc. Launches E-Commerce Marketplace Through Exactushemp.com and Initiates Buy Back Program for Non-Traceable CBD Products
03/10/2019 - 13:48 -
MediPharm Labs Sets Date to Announce Third Quarter 2019 Financial Results
03/10/2019 - 13:49 -
XBiotech annonce le premier patient dans une étude clinique visant à évaluer le bermekimab pour le traitement de la sclérose systémique
03/10/2019 - 13:53 -
Mesoblast Completes Successful Institutional Capital Raising of A$75 Million
03/10/2019 - 13:59 -
Kaleido Biosciences Presents Ex Vivo Data of KB109 Demonstrating Reduction of Multi-drug Resistant Pathogens at IDWeek 2019™
03/10/2019 - 14:00 -
Tonix Pharmaceuticals Announces Completion of Long-Term Exposure Studies in Participants with PTSD to Evaluate the Tolerability of TNX-102 SL 5.6 mg
03/10/2019 - 14:00 -
Albireo Recognizes PFIC Awareness Day and Highlights Urgent Needs of Progressive Familial Intrahepatic Cholestasis Families
03/10/2019 - 14:00 -
Spero Therapeutics Announces Positive Recommendation to Continue Phase 3 Clinical Trial of SPR994 as Planned Following Independent Review Committee Analysis of SPR994 Treated Patients in Lead-in Cohort of Trial
03/10/2019 - 14:00 -
Catalyst Biosciences Provides DalcA Phase 2b Trial Update
03/10/2019 - 14:00
Pages